Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicola De Rossi

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Therapeutics and Clinical Risk Management|August 6, 2021
Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and PharmacologyChiara Rosa Mancinelli, Nicola De Rossi, Ruggero Capra
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|August 12, 2014
Early detection and favourable outcome of natalizumab-related progressive multifocal leukoencephalopathy (PML) in two multiple sclerosis patientsCinzia Cordioli, Nicola De Rossi, Sarah Rasia, et al.
Journal of Neurovirology|August 10, 2017
Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathyLuca Prosperini, Cristina Scarpazza, Luisa Imberti, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|June 9, 2019
Four cases of natalizumab-related PML: a less severe course in extended interval dosing?Cristina Scarpazza, Nicola De Rossi, Giulietta Tabiadon, et al.
Plos One|December 21, 2016
Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent RegistryLuca Prosperini, Nicola de Rossi, Cristina Scarpazza, et al.
Annals of Neurology|October 13, 2017
To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathyCristina Scarpazza, Luca Prosperini, Nicola De Rossi, et al.
European Journal of Internal Medicine|May 15, 2020
Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumoniaRuggero Capra, Nicola De Rossi, Flavia Mattioli, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 5, 2020
Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumabChiara Rosa Mancinelli, Cristina Scarpazza, Cinzia Cordioli, et al.
Journal of Neuroimmunology|June 8, 2020
Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infectionMarco Chiarini, Simone Paghera, Daniele Moratto, et al.
Viral Immunology|August 25, 2017
Association Between BKPyV Serotype I Antibody Level and Natalizumab-Associated Progressive Multifocal LeukoencephalopathyFrancesca Rossi, Luca Prosperini, Nicola De Rossi, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Therapeutics and Clinical Risk Management|August 6, 2021
Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and PharmacologyChiara Rosa Mancinelli, Nicola De Rossi, Ruggero Capra
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|August 12, 2014
Early detection and favourable outcome of natalizumab-related progressive multifocal leukoencephalopathy (PML) in two multiple sclerosis patientsCinzia Cordioli, Nicola De Rossi, Sarah Rasia, et al.
Journal of Neurovirology|August 10, 2017
Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathyLuca Prosperini, Cristina Scarpazza, Luisa Imberti, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|June 9, 2019
Four cases of natalizumab-related PML: a less severe course in extended interval dosing?Cristina Scarpazza, Nicola De Rossi, Giulietta Tabiadon, et al.
Plos One|December 21, 2016
Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent RegistryLuca Prosperini, Nicola de Rossi, Cristina Scarpazza, et al.
Annals of Neurology|October 13, 2017
To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathyCristina Scarpazza, Luca Prosperini, Nicola De Rossi, et al.
European Journal of Internal Medicine|May 15, 2020
Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumoniaRuggero Capra, Nicola De Rossi, Flavia Mattioli, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 5, 2020
Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumabChiara Rosa Mancinelli, Cristina Scarpazza, Cinzia Cordioli, et al.
Journal of Neuroimmunology|June 8, 2020
Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infectionMarco Chiarini, Simone Paghera, Daniele Moratto, et al.
Viral Immunology|August 25, 2017
Association Between BKPyV Serotype I Antibody Level and Natalizumab-Associated Progressive Multifocal LeukoencephalopathyFrancesca Rossi, Luca Prosperini, Nicola De Rossi, et al.
Pageof 4